These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 29772697)
1. Structure-Activity Relationships Based on 3D-QSAR CoMFA/CoMSIA and Design of Aryloxypropanol-Amine Agonists with Selectivity for the Human β3-Adrenergic Receptor and Anti-Obesity and Anti-Diabetic Profiles. Lorca M; Morales-Verdejo C; Vásquez-Velásquez D; Andrades-Lagos J; Campanini-Salinas J; Soto-Delgado J; Recabarren-Gajardo G; Mella J Molecules; 2018 May; 23(5):. PubMed ID: 29772697 [TBL] [Abstract][Full Text] [Related]
2. 2D-QSAR and 3D-QSAR/CoMSIA Studies on a Series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-Phenylethan-1-ol with Human β₃-Adrenergic Activity. Apablaza G; Montoya L; Morales-Verdejo C; Mellado M; Cuellar M; Lagos CF; Soto-Delgado J; Chung H; Pessoa-Mahana CD; Mella J Molecules; 2017 Mar; 22(3):. PubMed ID: 28273884 [TBL] [Abstract][Full Text] [Related]
3. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking. Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866 [TBL] [Abstract][Full Text] [Related]
4. CoMFA and CoMSIA 3D-QSAR analysis of diaryloxy-methano-phenanthrene derivatives as anti-tubercular agents. Shagufta ; Kumar A; Panda G; Siddiqi MI J Mol Model; 2007 Jan; 13(1):99-109. PubMed ID: 16858589 [TBL] [Abstract][Full Text] [Related]
5. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models. Bhongade BA; Gadad AK J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035 [TBL] [Abstract][Full Text] [Related]
6. Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach. Babu S; Sohn H; Madhavan T Comput Biol Chem; 2015 Jun; 56():109-21. PubMed ID: 25935115 [TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents. Saqib U; Siddiqi MI SAR QSAR Environ Res; 2009 Jul; 20(5-6):519-35. PubMed ID: 19916112 [TBL] [Abstract][Full Text] [Related]
8. Structure based 3D-QSAR studies of Interleukin-2 inhibitors: Comparing the quality and predictivity of 3D-QSAR models obtained from different alignment methods and charge calculations. Halim SA; Zaheer-ul-Haq Chem Biol Interact; 2015 Aug; 238():9-24. PubMed ID: 26051521 [TBL] [Abstract][Full Text] [Related]
9. CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents. Vyas VK; Bhatt HG; Patel PK; Jalu J; Chintha C; Gupta N; Ghate M SAR QSAR Environ Res; 2013; 24(7):519-51. PubMed ID: 23305412 [TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA. Xu HR; Fu L; Zhan P; Liu XY SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445 [TBL] [Abstract][Full Text] [Related]
11. In-silico designing and characterization of binding modes of two novel inhibitors for CB1 receptor against obesity by classical 3D-QSAR approach. Khan N; Halim SA; Khan W; Zafar SK; Ul-Haq Z J Mol Graph Model; 2019 Jun; 89():199-214. PubMed ID: 30908997 [TBL] [Abstract][Full Text] [Related]
12. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs. Wu HQ; Yao J; He QQ; Chen FE SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254 [TBL] [Abstract][Full Text] [Related]
13. Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFalpha modulators. Avila CM; Romeiro NC; da Silva GM; Sant'Anna CM; Barreiro EJ; Fraga CA Bioorg Med Chem; 2006 Oct; 14(20):6874-85. PubMed ID: 16843662 [TBL] [Abstract][Full Text] [Related]
14. Structural insights of PA-824 derivatives: ligand-based 3D-QSAR study and design of novel PA824 derivatives as anti-tubercular agents. Inturi B; Pujar GV; Purohit MN J Recept Signal Transduct Res; 2015; 35(5):468-78. PubMed ID: 26053507 [TBL] [Abstract][Full Text] [Related]
15. Three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of tricyclic oxazolidinones as antibacterial agents. Gopalakrishnan B; Khandelwal A; Rajjak SA; Selvakumar N; Das J; Trehan S; Iqbal J; Kumar MS Bioorg Med Chem; 2003 Jun; 11(12):2569-74. PubMed ID: 12757724 [TBL] [Abstract][Full Text] [Related]
16. Investigations of Structural Requirements for BRD4 Inhibitors through Ligand- and Structure-Based 3D QSAR Approaches. Tahir A; Alharthy RD; Naseem S; Mahmood N; Ahmed M; Shahzad K; Akhtar MN; Hameed A; Sadiq I; Nawaz H; Muddassar M Molecules; 2018 Jun; 23(7):. PubMed ID: 29941841 [TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR CoMFA and CoMSIA on protein tyrosine phosphatase 1B inhibitors. Murthy VS; Kulkarni VM Bioorg Med Chem; 2002 Jul; 10(7):2267-82. PubMed ID: 11983524 [TBL] [Abstract][Full Text] [Related]
18. 3D QSAR studies on peroxisome proliferator-activated receptor gamma agonists using CoMFA and CoMSIA. Liao C; Xie A; Zhou J; Shi L; Li Z; Lu XP J Mol Model; 2004 Jun; 10(3):165-77. PubMed ID: 15022104 [TBL] [Abstract][Full Text] [Related]
19. Combined CoMFA and CoMSIA 3D-QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. Romero-Parra J; Chung H; Tapia RA; Faúndez M; Morales-Verdejo C; Lorca M; Lagos CF; Di Marzo V; David Pessoa-Mahana C; Mella J Eur J Pharm Sci; 2017 Apr; 101():1-10. PubMed ID: 28137469 [TBL] [Abstract][Full Text] [Related]
20. Synthesis, evaluation and CoMFA/CoMSIA study of nitrofuranyl methyl N-heterocycles as novel antitubercular agents. Wang A; Yang Y; Jun Y; Wang B; Lv K; Liu M; Guo H; Lu Y Bioorg Med Chem; 2018 May; 26(8):2073-2084. PubMed ID: 29551372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]